Nifedipine Sustained Release Tablets (II) 20mg*7/Box

• Customization: Available
• Application: Internal Medicine
• Usage Mode: For oral administration
• Suitable for: Elderly, Adult
• State: Solid
• Shape: Tablet
• Type: Inorganic Chemicals
• Pharmaceutical Technology: Chemical Synthesis
• Transport Package: Carton
• Specification: 20mg*7/box
• Trademark: SHIMEN
• Origin: China
• HS Code: 3004909099
• Production Capacity: 10000000

Product Description

Nifedipine Sustained Release Tablets (II)

Properties: This product is a yellow tablet.
Indications:Chronic stable angina pectoris (exertional angina); vasospasmodic angina (Prinzmetals angina, variant angina); Essential hypertension
Dosage: Please take this product according to the doctor's prescription, otherwise it will be difficult to achieve the best treatment effect.
The dose given should be individualized and should be based on the severity of the disease and the patient's response to the drug.
According to the patient's clinical symptoms, a standard dosing regimen is gradually established.
Patients with impaired liver function should be closely monitored and the dose should be reduced.
Patients with severe cerebrovascular disease should be treated with low doses.
Unless otherwise prescribed, the recommended dosage of this product is as follows:
Adults Standard dosing dose
Chronic stable angina 1 tablet 2 times daily
(exertional angina) (equivalent to nifedipine 40mg daily)
Vasospasmodic angina: 1 tablet 2 times a day
(Prinzmetal's angina, variant angina) (equivalent to nifedipine 40mg daily)
The standard dose is 20 mg twice daily; The dose can be increased to 40 mg twice a day.
Essential hypertension: 1 tablet 2 times daily
(equivalent to nifedipine 40mg daily)
The standard dose is 20 mg twice daily; The dose can be increased to 40 mg twice a day.
Method of administration:
This product should be taken whole with water after meals.
If taken with food, it can delay but not reduce the absorption of this product.
The interval between the two doses should not be less than 4 hours.
The use of this product should be discontinued gradually, especially at higher doses.

Shijiazhuang No.4 Pharmaceutical Co., Ltd. was established in 1948, now it is a large-sized foreign invested enterprise and comprehensive medicine manufacturer in China, the capital is USD58 million, and with more than 3000 employees. The company can manufacture 7 series medicines of more than 100 kinds and specifications including infusions, capsules, granules, tablets, oral liquids and etc with GMP approval by SFDA of China. For the key product of large volume I.V solution, the yearly output has reached more than 1200 million bottles including 40 million bottles packing with the soft plastic bottles in the dosage of 500 ml/ 250 ml /100ml. Some index such as quality, variety, and yearly output are all in the leading position of this field in China.  
The products have been sold to some countries and regions in South America, Africa, and Asia.